Search
The journey from biomarker candidate discovery to verification is complex and challenging. Traditional immunoassays, while commonly used, face limitations such as cross-reactivity and limited multiplexing capabilities. In contrast, targeted MS methods, particularly parallel reaction monitoring (PRM), offer a robust alternative by providing high accuracy, sensitivity, and reproducibility in peptide and protein quantification.
The Thermo Scientific Stellar mass spectrometer, with its dual-pressure linear ion trap, enhances PRM capabilities, enabling high-throughput analyses with exceptional precision and low detection limits. In this on-demand webinar Dr. Thomas will demonstrate how PRM on the Stellar MS can identify and prioritize predictive biomarkers of drug resistance in ovarian cancer.
Learning objectives:
- Discover how mass spectrometry is applied during the biomarker verification stage.
- Understand the advanced PRM capabilities of the Stellar MS for targeted MS applications.
- Gain insights into key concepts from consensus guidelines on peptide and protein quantification using targeted MS.
About the presenter
Dr. Stefani Thomas, Assistant Professor, Department of Laboratory Medicine and Pathology, University of Minnesota
Dr. Stefani Thomas earned her BA in Biological Sciences from Dartmouth College and her PhD in Pharmaceutical Sciences from the University of Southern California. After completing a research postdoctoral fellowship at Johns Hopkins, she joined the Center for Biomarker Discovery and Translation at Johns Hopkins Currently, Stefani is an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota. Her research laboratory applies mass spectrometry-based clinical proteomics to elucidate the biology of ovarian cancer.